Are the Patients in the Immune Tolerant Phase of Chronic Hepatitis B far from Hepatocellular Carcinoma or Death?

Nae-Yun Heo

doi:10.4166/kjg.2019.74.1.66

Journal List > Korean J Gastroenterol > v.74(1) > 1129965

Go to TopGo to Top Go to BottomGo to Bottom

See the article "".

TOOLS

Heo: Are the Patients in the Immune Tolerant Phase of Chronic Hepatitis B far from Hepatocellular Carcinoma or Death?

Research Update

The Korean Journal of Gastroenterology 2019; 74(1): 66-67.

Published online: 26 July 2019

DOI: https://doi.org/10.4166/kjg.2019.74.1.66

Are the Patients in the Immune Tolerant Phase of Chronic Hepatitis B far from Hepatocellular Carcinoma or Death?

Nae-Yun Heo

Department of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, Korea.

Correspondence to: Nae-Yun Heo, Department of Internal Medicine, Inje University Haeundae Paik Hospital, 875 Haeun-daero, Haeundae-gu, Busan, 48108, Korea. Tel: +82-51-797-0661, Fax: +82-51-797-0941, nyheo@hanmail.net

Korean Society of Gastroenterology

(open-access):

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Notes

^{Financial support} None.

^{Conflict of interest} None.

References

1. Wong GL. Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. Clin Mol Hepatol. 2018; 24:108–113.

2. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295:65–73.

3. Lim YS, Han S, Heo NY, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology. 2014; 147:152–161.

4. Kim GA, Lim YS, Han S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018; 67:945–952.

5. Chan HL, Chan CK, Hui AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology. 2014; 146:1240–1248.

6. Mason WS, Gill US, Litwin S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology. 2016; 151:986–998.e4.

7. Kim MN, Kim SU, Kim BK, et al. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. Hepatology. 2015; 61:1851–1859.

8. Sinn DH, Lee JH, Kim K, et al. A novel model for predicting hepatocellular carcinoma development in patients with chronic hepatitis B and normal alanine aminotransferase levels. Gut Liver. 2017; 11:528–534.

TOOLS

ORCID iDs: Nae-Yun Heo
https://orcid.org/0000-0001-6571-8935
Similar articles